Under a new directive from the Centers for Medicare and Medicaid Services (CMS), Medicare Advantage plans are now required to cover QALSODY® (tofersen), Biogen’s recently-approved treatment for people living with SOD1-ALS. We strongly support this new directive. Study results suggest …
December 2024 Foundation eNews
Empowering choices: Watch our new video on clinical research Deciding whether to join a clinical research study is a personal and significant choice for people living with ALS. To help empower these decisions, we’ve created a new video featuring Emma Schmidt …
Introducing the New Participating in Clinical Research Tool
Deciding whether to participate in clinical research is a pivotal step for people living with ALS and their families. It’s a process often filled with important questions about risks, benefits, and expectations. Clear and reliable information is essential to empower …
